Radiprodil

Radiprodil

SCHEMBL99256

O=C(Nc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GRIN1GRIN2B

The experimentally established mechanism targets of Radiprodil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
GRIN1 known ✓ Q05586 9/20 1.00
GRIN2B known ✓ Q13224 9/20 1.00
GRIN2D O15399 7/20 1.00
GRIN3B O60391 7/20 1.00
GRIN2A Q12879 7/20 1.00
GRIN2C Q14957 7/20 1.00
GRIN3A Q8TCU5 7/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Radiprodil SCHEMBL29819486 1.00 GRIN1 (1.00) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
Radiprodil SCHEMBL134435 0.99 GRIN1 (0.98) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
Radiprodil SCHEMBL135546 0.99 GRIN1 (0.98) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL4577953 0.93 GRIN1 (0.86) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL4576956 0.92 GRIN1 (0.84) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL4412049 0.91 GRIN1 (0.83) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL4414151 0.91 GRIN1 (0.83) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL4550674 0.91 GRIN1 (0.83) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL2264133 0.91 GRIN1 (1.00) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL4578785 0.90 GRIN1 (0.82) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9387212-B2 Methods for treating Parkinson's disease UCB BIOPHARMA SPRL (BE) 2016-07-12 US claimed
US-20120059034-A1 NOVEL CRYSTALLINE HYDRATE, AMORPHOUS AND POLYMORPHIC FORMS OF DIHYDRO-BENZOXAZOLE-6-YL-ACETAMIDE DERIVATIVE AND PROCESSES FOR THEIR PREPARATION RICHTER GEDEON NYRT. (HU) 2012-03-08 US claimed
CN-102341392-A Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation RICHTER GEDEON NYRT 2012-02-01 CN claimed
JP-2012500800-A 2012-01-12 JP claimed
JP-2012500801-A 2012-01-12 JP claimed
EP-2403850-A1 NOVEL CRYSTALLINE HYDRATE, AMORPHOUS AND POLYMORPHIC FORMS OF DIHYDRO-BENZOXAZOLE-6-YL-ACETAMIDE DERIVATIVE AND PROCESSES FOR THEIR PREPARATION Richter Gedeon Nyrt. (HU) 2012-01-11 EP claimed
JP-2011527689-A 2011-11-04 JP claimed
US-20110190347-A1 METHODS FOR TREATING NEUROPATHIC PAIN RICHTER GEDEON NYRT. 2011-08-04 US claimed
US-20110190348-A1 METHODS FOR TREATING CNS DISORDERS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2011-08-04 US claimed
EP-2331097-A1 METHODS FOR TREATING CNS DISORDERS Richter Gedeon Nyrt. (HU) 2011-06-15 EP claimed
WO-2010006020-A1 NOVEL CRYSTALLINE FORM OF 2-[4(4-FLUORO-BENZYL)-PIPERIDINE-1-YL]-2-OXO-N-(2-OXO-2,3-DIHYDRO-BENZOXAZOL-6-YL)-ACETAMIDE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-01-14 WO claimed
US-20100010044-A1 NOVEL CRYSTALLINE FORM OF 2-[4-(4-FLUORO-BENZYL)-PIPERIDINE-1-YL]-2-OXO-N-(2-OXO-2,3-DIHYDRO-BENZOXAZOL-6-YL)-ACETAMIDE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-01-14 US claimed
JP-4322113-B2 2009-08-26 JP claimed
US-7435744-B2 Piperidine derivatives as NMDA receptor antagonists GEDEON RICHTER VEGYESZETI GYAR RT (HU) 2008-10-14 US claimed
EP-1409477-B1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON NYRT (HU) 2008-09-17 EP claimed
JP-2005515968-A 2005-06-02 JP claimed
CN-1556805-A piperidine derivatives as NMDA receptor antagonists ������ҩ�����޹�˾ 2004-12-22 CN claimed
US-20040157886-A1 Piperdine derivatives as NMDA receptor antagonists UCB Biopharma SRL (BE) 2004-08-12 US claimed
EP-1409477-A1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 2004-04-21 EP claimed
WO-2003010159-A1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS Richter Gedeon Vegyészeti Gyár Rt. (HU) 2003-02-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157886-A1 Piperdine derivatives as NMDA receptor antagonists GRIN1, GRIN2D, GRIN2C GRIN1 1/4885GRIN2B 7/4885GRIN2D 2/4885
US-20100010044-A1 NOVEL CRYSTALLINE FORM OF 2-[4-(4-FLUORO-BENZYL)-PIPERIDINE-1-YL]-2-OXO-N-(2-OXO-2,3-DIHYDRO-BENZOXAZOL-6-YL)-ACETAMIDE UACA, CANX, AQP4 GRIN1 3414/4885GRIN2B 1866/4885GRIN2D 565/4885
US-20110190348-A1 METHODS FOR TREATING CNS DISORDERS SLC1A2, SLC18A2, BDNF GRIN1 105/4885GRIN2B 43/4885GRIN2D 13/4885
US-20120059034-A1 NOVEL CRYSTALLINE HYDRATE, AMORPHOUS AND POLYMORPHIC FORMS OF DIHYDRO-BENZOXAZOLE-6-YL-ACETAMIDE DERIVATIVE AND PROCESSES FOR THEIR PREPARATION DHX35, DHX9, ABCG2 GRIN1 3936/4885GRIN2B 3210/4885GRIN2D 938/4885
US-20110190347-A1 METHODS FOR TREATING NEUROPATHIC PAIN P2RX4, P2RX3, P2RX5 GRIN1 553/4885GRIN2B 372/4885GRIN2D 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.